Innogenetics N.V. (now Fujirebio Europe N.V.) was an international

in vitro diagnostics A medical test is a medical procedure performed to detect, diagnose, or monitor diseases, disease processes, susceptibility, or to determine a course of treatment. Medical tests such as, physical and visual exams, diagnostic imaging, genetic te ...

(IVD) company, with headquarters in

Ghent Ghent ( nl, Gent ; french: Gand ; traditional English: Gaunt) is a city and a municipality in the Flemish Region of Belgium. It is the capital and largest city of the East Flanders province, and the third largest in the country, exceeded in ...

, Belgium. Founded in 1985, the company developed and marketed IVD testing solutions as well as OEM raw materials. The company was acquired in September 2010 by Japanese

Fujirebio Fujirebio is a Japanese multinational biotechnology company, founded and headquartered in Tokyo, Japan, and present locally with offices in Japan, Asia, Europe and the United States and through a large international distribution network. The comp ...

Inc., an H.U. Group Holdings, Inc company, and changed name to Fujirebio Europe on October 1, 2013. The current CEO of Fujirebio Europe N.V. is

Christiaan De Wilde Christiaan De Wilde is a Belgian businessman, and he is at present the chief executive officer of the biotech company Fujirebio Europe NV, a member of Japan-based Fujirebio. Education Christiaan De Wilde in Accountancy at the ''Hogeschool Gent'' ...

History

Innogenetics was founded on 18 July 1985, by

Erik Tambuyzer Erik Tambuyzer (born 1949) is a Belgian bio-engineer and businessman. He is Chairman of the Board of the Flemish Center for Medical Innovation (CMI). Education Tambuyzer holds a doctoral degree in bio-industrial sciences from the Katholieke Uni ...

Hugo Van Heuverswyn Hugo Van Heuverswyn (born 1948) is a Belgian molecular biologist, biotech Biotechnology is the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular anal ...

and

Rudi Mariën Rudi Mariën is a Belgian scientist and businessman. He is chairman of the Belgian biotech company Innogenetics. Education Rudi Mariën obtained a degree in pharmaceutical sciences from the University of Ghent, specializing in clinical biology. ...

. In 1992, the company launched the first commercial tests for

cystic fibrosis Cystic fibrosis (CF) is a rare genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. Long-term issues include difficulty breathing and coughing up mucus as a result of frequent lung infections. O ...

Europe Europe is a large peninsula conventionally considered a continent in its own right because of its great physical size and the weight of its history and traditions. Europe is also considered a Continent#Subcontinents, subcontinent of Eurasia ...

(INNO-LiPA CFTR) and in 1993 the first commercial test for

Hepatitis C virus The hepatitis C virus (HCV) is a small (55–65 nm in size), enveloped, positive-sense single-stranded RNA virus of the family ''Flaviviridae''. The hepatitis C virus is the cause of hepatitis C and some cancers such as liver cancer ( hepato ...

(HCV)

genotyping Genotyping is the process of determining differences in the genetic make-up (genotype) of an individual by examining the individual's DNA sequence using biological assays and comparing it to another individual's sequence or a reference sequence. ...

worldwide (INNO-LiPA HCV). In 1995, the first commercial Alzheimer's disease research test for hTau was launched (INNOTEST hTau Ag). In 1998, the company launched the first commercial Alzheimer's disease research test for β-

Amyloid Amyloids are aggregates of proteins characterised by a Fibril, fibrillar morphology of 7–13 Nanometer, nm in diameter, a beta sheet (β-sheet) Secondary structure of proteins, secondary structure (known as cross-β) and ability to be Staining, ...

and in 2002 the first commercial test for

Hepatitis B virus ''Hepatitis B virus'' (HBV) is a partially double-stranded DNA virus, a species of the genus ''Orthohepadnavirus'' and a member of the ''Hepadnaviridae'' family of viruses. This virus causes the disease hepatitis B. Disease Despite there bein ...

(HBV) genotyping (INNO-LiPA HBV Genotyping). The company was one of the first biotech companies to be listed on a European

stock exchange A stock exchange, securities exchange, or bourse is an exchange where stockbrokers and traders can buy and sell securities, such as shares of stock, bonds and other financial instruments. Stock exchanges may also provide facilities for th ...

, in 1996 it was the first biotech company listed on EASDAQ, now

NASDAQ The Nasdaq Stock Market () (National Association of Securities Dealers Automated Quotations Stock Market) is an American stock exchange based in New York City. It is the most active stock trading venue in the US by volume, and ranked second ...

Europe. Until 2008 Innogenetics had its shares traded on

Euronext Euronext N.V. (short for European New Exchange Technology) is a pan-European bourse that offers various trading and post-trade services. Traded assets include regulated equities, exchange-traded funds (ETF), warrants and certificates, bonds, de ...

Brussels Brussels (french: Bruxelles or ; nl, Brussel ), officially the Brussels-Capital Region (All text and all but one graphic show the English name as Brussels-Capital Region.) (french: link=no, Région de Bruxelles-Capitale; nl, link=no, Bruss ...

. Innogenetics N.V. was acquired by

in 2010 and changed name to Fujirebio Europe N.V. on October 1, 2013.

External links

Fujirebio website in EnglishH.U. Group website in English
{{Authority control Biotechnology companies of Belgium Pharmaceutical companies of Belgium Companies based in East Flanders